Morning trading has seen the FTSE 100 drop 60 points, mirroring losses in Europe as indices continue to fall from recent highs.
Virus news hits a vulnerable market.
Little fresh positive news to drive overextended indices higher.
Kingfisher weakens after Q3 sales figures.
Virus fears have hit an overextended global stock market this morning, knocking European equities sharply lower and pointing towards a weaker start in the US. After the soaraway gains of the past two weeks, equities now look much more richly-valued, and thus vulnerable to an outbreak of bad news. This is precisely what we got in the form of spreading infections in the US but also in Japan, a worrying sign indeed for a country that had been successful earlier in the year in controlling the spread. Even reports of success for AstraZeneca's new vaccine were not enough, the impact of these vaccine announcements having been on a declining trend since the first, excitedly-received news from Pfizer almost three weeks ago. There appears to be little desire to chase equities at these levels, and perhaps rightly so, with markets looking priced for perfection and still vulnerable to some short-term turbulence.
Speaking of things looking priced for continued good news, Kingfisher has fallen 4% after reporting a strong set of sales figures for Q3. The news appears to more than justify the huge gains in the shares since March, up 120% versus a mere 22% for the index. But while the overall investment case remains strong, investors appear content for now to sit and await a better chance to buy back in later in the year.
Ahead of the open, we expect the Dow to start at 29,257, down 181 points from Wednesday's close.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.